P595 Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease

MLA

C Muñoz-Villafranca, et al. “P595 Time of Therapeutic Drug Monitoring of Infliximab during Induction and Its Relationship with Clinical Remission in Inflammatory Bowel Disease.” Journal of Crohn’s and Colitis, vol. 17, Jan. 2023, p. i723. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjac190.0725.

APA

C Muñoz-Villafranca, P Arreba, M Gomez, N Ispizua Madariaga, L Buendia, M L Lopez, A Ugarte, I de la Fuente, N Prado, L Irusta, M A Jimenez, M Santa Cruz, M Gonzalez, A Bilbao, & J Ortiz de Zárate. (2023). P595 Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 17, i723. https://doi.org/10.1093/ecco-jcc/jjac190.0725

Chicago

C Muñoz-Villafranca, P Arreba, M Gomez, N Ispizua Madariaga, L Buendia, M L Lopez, A Ugarte, et al. 2023. “P595 Time of Therapeutic Drug Monitoring of Infliximab during Induction and Its Relationship with Clinical Remission in Inflammatory Bowel Disease.” Journal of Crohn’s and Colitis 17 (January): i723. doi:10.1093/ecco-jcc/jjac190.0725.